Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SMGene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 14(18): 5893-5899

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Clinical Cancer Research (Impact Factor: 8.19). 10/2008; 14(18):5893-9. DOI: 10.1158/1078-0432.CCR-07-4762
Source: PubMed

ABSTRACT To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD).
Twenty patients with inflammatory breast cancer and one patient with locally advanced breast cancer received one cycle of bevacizumab followed by six cycles of bevacizumab plus docetaxel-doxorubicin before surgery. Baseline angiogenic/tumor markers were examined by immunohistochemistry and gene expression profiles were measured by Agilent Whole Human Genome arrays. All were assessed for clinical response.
Fourteen patients (67%, 95% confidence interval, 43-85.4%) had PR, five had SD, and two had PD. Expression of CD31 and platelet-derived growth factor receptor-beta (PDGFR-beta) in the tumor vasculature by immunohistochemistry was significantly associated with response (PR versus SD/PD; CD31 median, 33.5 versus 13.2; P = 0.0004; PDGFR-beta median, 5.9 versus 0.6; P = 0.01). Tumor VEGF-A showed a trend towards association with response (2.65 versus 0.25; P = 0.04). pVEGFR2(Y996), pVEGFR2(Y951), MVD, Ki67, apoptosis, grade, ER, HER-2/neu, and p53 were not associated with response. Twenty-six of 1,339 Gene Ontology (GO) classes at the gene transcriptional level were differentially expressed between patients with PR and SD/PD (P < 0.005). Representative significant GO classes include spindle (11 genes; P = 0.001), vascular endothelial growth factor receptor activity including PDGFR-beta (5 genes; P = 0.002), and cell motility including CD31 (80 genes; P = 0.005).
Baseline CD31, PDGFR-beta, and GO classes for vascular endothelial growth factor receptor activity and mitosis were significantly associated with response to bevacizumab followed by bevacizumab plus chemotherapy.

Download full-text


Available from: Sherry X. Yang, Aug 19, 2015
  • Source
    • "Indeed, numerous examples have been recently published in the scientific literature that support the importance of small translational trials to proceed with the scientific knowledge about biomarkers related to BV-based therapies and to develop them for future clinical trials. For example, Brostjan et al (2008) showed significant variations of VEGF and TSP-1 plasma levels after treatment with BV in 19 patients, whereas Yang et al (2008) correlated some angiogenic markers (CD31 and PDGFR-b) and the response to neoadjuvant BV in 21 patients with breast cancer. Moreover, recently Jain's group has published significant evidences of the up-regulation of SDF1a, CXCR4, CXCL6 and neuropilin 1 after treatment with BV in just 12 rectal cancer patients (Xu et al, 2009), confirming the importance of small translational trial to identify a novel but 'necessary and critical insight for guiding further therapy' (Xu et al, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal cancer (mCRC). Plasma levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble VEGF receptor 2 (sVEGFR-2) and thrombospondin-1 (TSP-1) were assessed by ELISA assay at different time points in a cohort of 25 patients enroled in a phase II trial of GONO-FOLFOXIRI plus BV as first-line treatment of mCRC. VEGF: -2578A/C, -1498C/T, -1154A/G, -634C/G and 936C/T; and VEGFR-2: -604A/G, +1192C/T and +1719A/T, polymorphisms were assessed in a total of 54 patients. Treatment with GONO-FOLFOXIRI plus BV determined a prolonged and significant reduction in plasma free, biologically active VEGF concentration. Interestingly, VEGF concentrations remained lower than at baseline also at the time of PD. Conversely, PlGF levels increased during the treatment if compared with baseline, suggesting a possible role in tumour resistance; moreover, sVEGFR-2 increased at the time of PD, as well as TSP-1. No association of assessed polymorphisms with outcome was found. Our study suggested the possible mechanisms of resistance to combined therapy in those patients with a progressive disease to be tested in ongoing phase III randomised studies.
    British Journal of Cancer 03/2011; 104(8):1262-9. DOI:10.1038/bjc.2011.85 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In der neoadjuvanten und adjuvanten Therapie des Mammakarzinoms nimmt die zielgerichtete Therapie einen zunehmend größeren Stellenwert ein. Trastuzumab hat für alle Subgruppen der Patientinnen mit Her2-positivem Rezeptorstatus die Prognose wesentlich verbessert und ist derzeit die einzige zielgerichtete Substanz, die für die Adjuvanzsituation zugelassen ist. Als Tyrosinkinasehemmer wirkt sich Lapatinib ebenfalls auf den Her2-Rezeptor aus, es wird als Monosubstanz, in Kombination und Sequenz derzeit in Studien beim frühen Mammakarzinom geprüft. Bevacizumab ist die bereits am weitesten untersuchte Substanz mit Wirkung auf das VEGF-System. Die antiangiogenetische Therapie ist in der metastasierten Situation etabliert und wird derzeit in adjuvanten und neoadjuvanten Therapiedesigns geprüft. Ein Schwerpunkt der klinischen Forschung besteht darin, den Tumor nicht nur morphologisch, sondern molekularbiologisch genauer zu charakterisieren. Auf dieser Basis könnten Patientinnen für bestimmte Therapien gezielt selektiert werden, um so ihre Prognose zu verbessern. Die derzeit laufenden Phase-III-Studien werden hierzu einen wichtigen Beitrag leisten können. Specific goal-oriented therapy is increasingly gaining significance in neoadjuvant and adjuvant breast cancer therapy. For all subgroups of Her2-positive receptor patients trastuzumab provides a substantially improved prognosis and is presently recognised as the only target-oriented substance admitted to adjuvant treatment. Similar to tyrosine kinase inhibitors, lapatinib has an effect on the Her2 receptor and is currently being examined as a monosubstance both in combination and sequence as a part of studies in the early stages of breast cancer. Bevacizumab is already the most extensively examined substance with an affect on the VEGF system. Antiangiogenetic therapy is well-established in the metastasized situation and is currently being examined in adjuvant and neoadjuvant therapy designs. The existing focal point of clinical research is to precisely characterise the tumour not only morphologically but also molecular biologically. Accordingly, patients can be selected for specific therapies in order to improve the prognosis. For these reasons the current phase III studies can be expected to achieve an important contribution to breast cancer therapy.
    Der Gynäkologe 01/2009; 42(3):157-163. DOI:10.1007/s00129-008-2295-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite advances in breast cancer treatment and outcome over the last two decades, women continue to relapse and die of advanced disease. Historically, estrogen and progesterone receptor expression, HER2 overexpression and clinico-pathologic parameters have guided therapeutic decision making. However, there are limits to the risk estimation provided by these parameters, leading to potential overtreatment of low-risk disease and undertreatment of poor-risk disease. Genomic technologies now provide the opportunity to refine our therapeutic approach by individualizing treatment to patients' individual tumor profiles. Gene profiles or signatures are groupings of genes that are differentially expressed between tumors, reflecting differences in biologic behavior. Prognostic gene signatures stratify breast cancer patients by tumor natural history, regardless of the treatment employed. Currently, there are three commercially available prognostic gene signatures: Oncotype DX (Genomic Health, Inc.), MammaPrint (Agendia BV), and the HOXB13/IL17BR (H/I) ratio; (Theros H/ISM; bioTheranostics). Others under development include the Intrinsic Gene Set, the Rotterdam Signature, the Wound Response Indicator, and the Invasive Gene Signature. Predicative signatures classify patients based on responsiveness to specific therapies. Of the prognostic signatures, Oncotype DX has been shown to have predictive value for the incremental benefit of chemotherapy when added to a hormonal therapy regimen. Additional genetic profiles under development predict response to specific hormonal therapies, anthracyclines, and taxanes. Gene signatures have the potential to transform breast cancer treatment as it becomes tailored to each patient's tumor expression profile and significantly improve the outcomes of this disease.
    Molecular Diagnosis & Therapy 02/2009; 13(2):73-90. DOI:10.1007/BF03256317 · 2.59 Impact Factor
Show more